Hematology presentation from internal département Pts.pptx

Hematology presentation from internal département

1. Name, Dx & clinical data Investigations Mgt, Plan & remarks TYOBISTA ANDUALEM, 22/F IC:304463 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On Intrim Maintainace course III of PI CALGB10403 ALL Protocol P1:T Cell Lymphoblastic Lymphoma. Subjectively No complian P/E: stable Days on IM 15th 16th 17th 18th 19th Omeprazole 20mg po BID CPT 960mg po 3x week Plan RFT, LFT , ELE WBC 4k 2.4k 2.7k 3.7k ANC 2.9k 1.5k 1.5k 2.6k HGB 10.1 9.6 9.6 9.9 MCV 92.8 92.7 93.4 93.3 PLT 574k 490k 533k 552k Na K Cl Cr /Ur ALT/AST/ALP TB/DB

2. Name, Dx & clinical data Investigations Mgt, Plan & remarks WONDALE ZELEKE, 17/M IC:303851 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On Intrim Maintainace course III PI CALGB10403 ALL Protocol (TKI based) P1: Ph + ve ALL P2: NF of ?chest focus (treated 10 days back) Subjectively No complain P/E: stable Days on IM 11th 12nd 13rd 14th 15th Omeprazole 20mg po BID CPT 960mg po 3x week hydrocortisone cream WBC 4.5k 8.8k 4.8k 2.9k ANC 1.9k 7k 2.4k 1.4k HGB 10.7 10.8 9.7 10.5 MCV 93.8 94.8 94.6 93.6 PLT 375k 277k 194k 183k Na K Cl Cr /Ur 0.5 /32.6 ALT/AST/ALP ?/46 /87 TB/DB 0.2 /0.1 CSF Analysis; on WBC (leukocytes) count: 12 cells MN%: 100 CSF Analysis; on Feb 26/2025 WBC (leukocytes) count: 5 cells MN: 80% PMN: 20%

3. Name, Dx & clinical data Investigations Mgt, Plan & remarks SELAMAWIT SERWANA, 26/F IC:290602 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On Delay Intensification course IV of PI CALGB10403 ALL Protocol P1: ph-ve ALL P2: Left lower limb proximal DVT P3: Neutropenic fever of ?chest focus + thrombophlebitis Subjectively Fver , iv line site mild swelling , dry cough Started today otherwise no chest pain, no SOB, GI or urinary complain P/E: looks stable V/s BP: 105/70mmhg PR: 130b/m RR:24/m T: 38.4 one record. spo2: 94% @room air cherst: MSK: 3days ago she took cytarabine & L-aspargenase today she had L-aspargenase Days on DI 43rd 44th 45th 46th 47th Tadays Activity Transfused 4 units of Platelate yesterday Transfused PRBC 1 Unit today (will take the 2nd after this) Cefepeme 2gm IV TID Vancomycine 1gm IV BID DISCONTINUED revaroxan 20mg po daily GCSF 300mcg SC daily Acyclovir 400mg po BID Fluconazole 200mg po daily Omeprazole 20mg po BID PLAN: Septic workup (blood culture bottle is not available at H.C) Platelate Transfusion to transfer TASH if bed available WBC 1.3k 800 500 600 ANC 1k 800 400 500 HGB 7.3 6.9 7.9 6.1 MCV 90.8 89.1 87.7 87.3 PLT 122k 62k 21k 22k Na K Cl Cr /Ur 0.3 /32 ALT/AST/ALP ?/25 /126 TB /DB 1.14 /0.36

4. Name, Dx & clinical data Investigations Mgt, Plan & remarks KASU ADUGNA, 43/M IC:299735 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On Delay Intensification course IV of PI CALGB10403 ALL Protocol P1: Ph -ve ALL Subjectively No complian P/E: stable Days on DI 32nd 33rd 34th 35th 36th Omeprazole 20mg po BID CPT 960mg po 3x week WBC 3.3K 3.3k 2k 5.3k ANC 1.1K 1.6k 600 4k ? HGB 13.6 13.6 13.1 13.2 MCV 88.5 86.9 88.8 87.2 PLT 352K 329k 283k 258k Na K Cl Cr /Ur 0.6/20 ALT/AST/ALP ?/25/60 TB/DB 0.5/0.16

5. Name, Dx & clinical data Investigations Mgt, Plan & remarks HABIBA MOHAMMAD, 14/F IC:294419 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On 4th CYCLE OF ATO & ATRA Plan RFT, LFT , ELE P1: APL Subjectively No complian P/E: stable Days on DI 1st 2nd 3rd 4th WBC 10.3 7.5k ANC 7.4k 4.9k HGB 13.3 14.3 MCV 86.1 86.4 PLT 331k 158k Na 144 K 4.5 Cl 104.7 Cr /Ur 0.4/16.3 ALT/AST/ALP 79/24/111 TB/DB

6. Name, Dx & clinical data Investigations Mgt, Plan & remarks SIMACHEW AMARE, 25/M IC:253955 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On 3rd CYCLE OF ATO & ATRA P1: APL Subjectively No complian P/E: stable Days on DI 1st 2nd 3rd 4th Plan: RFT, LFT , ELE WBC 7.1k 13.6 ANC 4.1 10.3 HGB 15.9 16.1 MCV 87.8 89.1 PLT 279k 268k Na 148 K 4.4 Cl 107 Cr /Ur 0.6/25 ALT/AST/ALP 36/34/85 TB/DB

7. Name, Dx & clinical data Investigations Mgt, Plan & remarks NASIR IBRAHIM, 18M IC= 305236 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On Intrim Maintainace course III of PI CALGB10403 ALL Protocol P1: T cell lymphoblastic Lymphoma Subjectively No complian P/E: stable Days on DI 1st 2nd Acyclovir 400mg po BID Fluconazole 200mg po daily O meprazole 20MG PO BID CPT 960 3x/week Plan: CBC, RFT, LFT , ELE WBC 2.4K 2k ANC 1.9K 900 HGB 8.5 8.3 MCV 83.6 85 PLT 247K 231K Na 132 K 3.63 Cl 105.8 Cr /Ur 0.6/24 0.6/30 ALT/AST/ALP ?/24/103 ?/21/141 TB/DB

8. Name, Dx & clinical data Investigations Mgt, Plan & remarks HABTAMU SISAY, 22/M IC= 304266 Date Feb 24, 2025 Feb 25, 2025 Feb 26, 2025 Feb 27, 2025 Feb 28, 2025 On Intrim Maintainace course III of PI CALGB10403 ALL Protocol P1: P1: Ph + ve ALL P2: NF of 2ry to Mucositis (treated 7 days back) Subjectively No complian P/E: stable Days on DI 1st 2nd Plan: CBC, RFT, LFT , ELE Acyclovir 400mg po BID Fluconazole 200mg po daily CPT 960 mg 3x/week Omeprazole 20mg po BID GCSF 300mcg SC daily Remarks He was on Triple IT chemotherapy 2x aweekly but only give 2 times since his platelate was very low through entier early consolidation phase) his current platelate is also low so first day IT MTX of intrime maintainace was not Give WBC 600 800 ANC 100 100 HGB 9.3 9 MCV 83.5 83 PLT 10K 9K Na 136 K 3.35 Cl 107.3 Cr /Ur 0.3/15.6 0.3/18 ALT/AST/ALP ?/9.7/57 ?/13/63 TB/DB 0.4/0.1